



BILLING & CODING GUIDE



Coverage, Coding, & Payment for ZYNYZ



Best Practices for Timely Reimbursement



Example Claims Forms – CMS-1500 & CMS-1450



Provider Readiness – Process and Tips



IncyteCARES for ZYNYZ – Patient Support Program Overview

This Billing and Coding Guide is intended to provide an overview of coding and coverage information for ZYNYZ. Please use this guide to support the reimbursement process and as a source of information on IncyteCARES for ZYNYZ.

While this guide provides information on navigating the reimbursement process, please note all enclosed coding information is for reference purposes only and is not intended to serve as guidance for specific coding, billing, and claims submissions. Decisions on which codes best describe the services provided must be made by individual providers based on specific payer guidance and requirements.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

For questions regarding ZYNYZ reimbursement and access, please call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM – 8 PM ET.

Coverage and payment methodology for ZYNYZ will vary by payer type.

For Medicare patients, ZYNYZ will be covered under Medicare Part B when used for an FDA-approved indication and when medically reasonable and necessary.

There are no prior authorization requirements for ZYNYZ under traditional fee-for-service Medicare plans.

For patients enrolled in a commercial health plan, Medicare Advantage, or Medicaid, coverage of ZYNYZ will vary by payer. Some payers may also apply utilization restrictions for ZYNYZ. When seeking coverage, providers should be prepared for the possibility of needing to go through the prior authorization process.

PAYMENT METHODOLOGY



MEDICARE

Standard Medicare Part B reimbursement is Average Sales Price (ASP) + 6%.*



COMMERCIAL PAYERS & MEDICAID

Drug reimbursement will vary by payer but is generally the contracted reimbursement rate between the payer and provider.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

*If Medicare sequestration is in effect, a statutory reduction to the payment is applied. Please visit [CMS.gov](https://www.cms.gov) for more information.

INDICATIONS & USAGE

Squamous Cell Carcinoma of the Anal Canal

ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).

ZYNYZ, as a single agent, is indicated for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Important immune-mediated adverse reactions listed may not be inclusive of all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can occur at any time after starting or discontinuing treatment with a PD-1/PD-L1-blocking antibody, and can affect more than one body system simultaneously.

Monitor patients closely for symptoms and signs that may be clinical manifestations of such reactions. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1-blocking antibodies. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. If suspected, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue ZYNYZ depending on severity. In general, if ZYNYZ requires interruption or discontinuation, administer systemic corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) until improvement to \leq Grade 1. Then, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroids.

Please see additional Important Safety Information throughout.
Please see the Full [Prescribing Information](#).

Please refer to the coding information below to support appropriate claims processing for ZYNYZ for the treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC). Payer requirements for coding may vary. For the most accurate list of codes and billing requirements, please confirm with the individual payer.

NATIONAL DRUG CODES (NDCs)		
	10-Digit	11-Digit
500 mg/20 mL (25 mg/mL) Single-Dose Vial	50881-006-03	50881-0006-03

HCPCS CODING	
J9345	Injection, retifanlimab-dlwr, 1 mg

HCPCS MODIFIER	
JZ	Zero drug amount discarded/not administered to any patient

SCAC ICD-10-CM DIAGNOSIS CODES	
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasms of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal

REVENUE CODES			
Administration		Drug	
0335	Chemotherapy Administration - IV	0636	Drugs requiring detailed coding

DRUG ADMINISTRATION / CPT® CODE	
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; IV, intravenous.

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Immune-Mediated Pneumonitis

ZYNYZ can cause immune-mediated pneumonitis. Immune-mediated pneumonitis occurred in 3% (13/440) of patients, including fatal (0.2%), Grade 3 (0.9%), and Grade 2 (1.4%) reactions. Pneumonitis led to permanent discontinuation of ZYNYZ in 1 patient and withholding in 0.9%.

Systemic corticosteroids were required in 77% (10/13) of patients. Pneumonitis resolved in 10 of the 13 patients.

Immune-Mediated Colitis

ZYNYZ can cause immune-mediated colitis. Cytomegalovirus infections/reactivations have occurred in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1-blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

Please see additional Important Safety Information throughout.

Please see the Full Prescribing Information.

BEST PRACTICES FOR TIMELY CLAIMS REIMBURSEMENT



EFFECTIVE OCTOBER 1, 2023, ZYNZY HAS A UNIQUE J-CODE

J9345

Injection, retifanlimab-dlwr, 1 mg

One single-dose vial of ZYNZY contains 500 mg of retifanlimab-dlwr, equal to 500 billing units when using HCPCS code J9345.



Payer requirements regarding detailed claim form information may vary. It is important to check with individual payers on their specific requirements and ensure accurate documentation of services and units of measure.

For an efficient claims and reimbursement process, employ the following strategies:

- ▶ **Verify accuracy** of patient information
- ▶ **Use the ZYNZY specific J-code:** J9345 (Injection, retifanlimab-dlwr, 1 mg) when completing a claim
- ▶ **Ensure accurate coding** - refer to the ZYNZY Billing & Coding Guide for appropriate codes and modifiers
 - Reference the included Example Claims Forms for guidance on accurately recording appropriate codes and supplemental information
- ▶ **Include correct number** of units administered. Note - one 500 mg single-dose vial is equal to 500 billing units
- ▶ **Include correct modifier** to report no product discarded - record the JZ Modifier on the same line as the HCPCS code
- ▶ **Ensure accuracy** of information needed to process the claim
 - Correct NDC Format - use 10- or 11-digit format based on payer requirements
 - Prior Authorization Number, if applicable
- ▶ **Check your payer agreements** to ensure you understand any specific reimbursement needs for ZYNZY and follow the payer's recommendations for providing additional information (e.g., medical records)
- ▶ **Make sure** electronic claims are successfully submitted
- ▶ **Stay up to date** with payer coverage policies

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

For questions regarding billing, coding, or reimbursement for ZYNZY, call IncyteCARES to be connected with a Field Access Manager



1-855-452-5234
M-F, 8 AM to 8 PM ET

The information herein is provided for educational purposes only. Insurance coverage and reimbursement are not guaranteed. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

ZYNZY as a Single Agent: Immune-mediated colitis occurred in 1.6% (7/440) of patients, including Grade 4 (0.2%), Grade 3 (0.2%), and Grade 2 (0.7%). Colitis led to permanent discontinuation of ZYNZY in 1 patient and withholding in 0.9%. Systemic corticosteroids were required in 71% (5/7) of patients. Colitis resolved in 4/7 patients.

Please see additional Important Safety Information throughout.
Please see the Full [Prescribing Information](#).

ZYNYZ EXAMPLE CMS-1500 CLAIM FORM

PHYSICIAN OFFICE SETTING



This example form is provided for guidance and reference only.

ZYNYZ and the associated services provided in a physician office setting are billed on the CMS-1500 Claim Form. It is always the provider's responsibility to determine the appropriate healthcare setting, and to submit true and correct claims for the products and services rendered. **Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.**

Box 19

Some payers may require additional information for proper processing. This may include*: *Drug name, strength, route of administration, dosage administered, and NDC*

Box 21

Enter the ICD-10-CM diagnosis code

Box 24 A-B

Enter the date of service and appropriate place of service code. If NDC reporting is required, include the following in the shaded portion of Box 24A*: *N4+11-Digit NDC+ML+Unit quantity administered*

Box 24 D

Enter the appropriate HCPCS, modifier, and CPT®, codes. For example:

- ▶ Drug - J9345 (Injection, retifanlimab-dlwr, 1 mg)
- ▶ Modifier - JZ (Include the JZ modifier on the same line as the HCPCS code to indicate no amount of drug was discarded)
- ▶ Administration - 96413 (Chemo infusion for 1st hour, single or initial drug)

Box 24 E

Refer to the diagnosis (Box 21), relating to the drug or procedure listed in Box 24D

Box 24 G

Enter number of units for each line item

- ▶ J9345 Billing Unit = 1 mg
- ▶ Single-Dose Vial = 500 mg
- ▶ 500 mg Vial = 500 Units

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

☐ PICA ☐ PICA

1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN (ID#) ☐ FECA BLK/LUNG (ID#) ☐ OTHER (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM/DD/YY) SEX ☐ M ☐ F

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED Set ☐ Spouse ☐ Child ☐ Other ☐

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

a. OTHER INSURED'S POLICY OR GROUP NUMBER

a. EMPLOYMENT? (Current or Previous) ☐ YES ☐ NO

b. RESERVED FOR NUCC USE

b. AUTO ACCIDENT? ☐ YES ☐ NO PLACE (State)

c. RESERVED FOR NUCC USE

c. OTHER ACCIDENT? ☐ YES ☐ NO

d. INSURANCE PLAN NAME OR PROGRAM NAME

10d. CLAIM CODES (Designated by NUCC)

d. IS THERE ANOTHER HEALTH BENEFIT PLAN? ☐ YES ☐ NO # yes, complete items 9, 9a, and 9d.

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

SIGNED DATE

14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) QUAL. 19

15. OTHER DATE QUAL. 24 A-B

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM/DD/YY TO MM/DD/YY

17a. REFERRING PROVIDER OR OTHER SOURCE 17b. NPI

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM/DD/YY TO MM/DD/YY

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB? ☐ YES ☐ NO \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS, INJURY, or PREGNANCY (Relate NDC to service line below (24E)) ICD 10d. 24 E

22. RESUBMISSION ☐ YES ☐ NO ORIGINAL REF. NO. 24 G

a. DX Code 24 A-B

24. A. DATE(S) OF SERVICE From MM/DD/YY To MM/DD/YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (CPT/HCPCS) E. DIAGNOSIS POINTER F. \$ CHARGES G. DATE OF UNITS H. EPSI (Per Unit) I. ID. QUAL. J. RENDERING PROVIDER ID. #

1. N45088100603 ML20 11 J9345 JZ A \$ 500 NPI

2. MM/DD/YY MM/DD/YY 11 96413 A \$ 1 NPI

3. NPI

4. NPI

5. NPI

6. NPI

25. FEDERAL TAX ID. NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (Do not check, see text) YES NO 28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Rev'd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH #

SIGNED DATE a. NPI b. NPI

NUCC Instruction Manual available at: www.nucc.org

*Always refer to specific payer policies as billing requirements may vary by payer, including use of the 10- or 11-digit NDC.

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

ZYNYZ in Combination with Carboplatin and Paclitaxel: Immune-mediated colitis occurred in 10% (16/154) of patients receiving ZYNYZ in combination with carboplatin and paclitaxel, including Grade 4 (0.6%), Grade 3 (2.6%), and Grade 2 (3.2%). Colitis led to permanent discontinuation of ZYNYZ in 2 patients and withholding of ZYNYZ in 2 patients. Systemic corticosteroids were required in 94% (15/16) of patients. Colitis resolved in 15 of the 16 patients.

Please see additional Important Safety Information throughout.

Please see the Full Prescribing Information.

ZYNYZ EXAMPLE CMS-1450 CLAIM FORM

HOSPITAL OUTPATIENT SETTING



This example form is provided for guidance and reference only.

ZYNYZ and the associated services provided in a hospital outpatient setting are billed on the CMS-1450 Claim Form (or UB-40). It is always the provider's responsibility to determine the appropriate healthcare setting, and to submit true and correct claims for the products and services rendered. **Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.**

Box 42

List the appropriate revenue code for each service provided. Drugs billed with HCPCS codes usually require revenue code 0636 (drugs requiring detailed coding)

Box 43

Enter a description for each revenue code. If NDC reporting is required, include the following*: *N4+11-Digit NDC+ML+Unit quantity administered*

Box 44

Enter the appropriate HCPCS, modifier, and CPT® codes. For example:

- ▶ Drug - J9345 (Injection, retifanlimab-dlwr, 1 mg)
- ▶ Modifier - JZ (Include the JZ modifier on the same line as the HCPCS code to indicate no amount of drug was discarded)
- ▶ Administration - 96413 (Chemo infusion for 1st hour, single or initial drug)

Box 45

Enter the date of service

Box 46

Enter number of units for each line item

- ▶ J9345 Billing Unit = 1 mg
- ▶ Single-Dose Vial = 500 mg
- ▶ 500 mg Vial = 500 Units

Box 67

Enter the ICD-10-CM diagnosis code

1		2		3		4	
PATIENT NAME		PATIENT ADDRESS		PATIENT CITY/STATE/ZIP		PATIENT PHONE	
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION	
14 TYPE		15 SRC		16 DNR		17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29	
30		31		32		33	
34		35		36		37	
38		39		40		41	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826							

PROVIDER READINESS - PROCESS & TIPS



When preparing to treat a patient with ZYNZY for Squamous Cell Carcinoma of the Anal Canal (SCAC), consider the steps below to facilitate patient access, proper claims submission, and appropriate reimbursement. For questions or support on any of these steps, please reach out to IncyteCARES for ZYNZY at **1-855-452-5234** or visit **HCP.IncyteCARES.com/ZYNZY** to complete an Enrollment Form.

- 1 — **Research and understand** patient-specific benefits and coverage for ZYNZY
- 2 — If there are access concerns, be sure to **enroll your patient** in IncyteCARES to understand potential financial assistance options that may be available for eligible patients
- 3 — **Schedule the patient** for his or her first ZYNZY infusion
- 4 — **Purchase ZYNZY** (if not already in inventory) through one of the following Specialty Distributors:

SPECIALTY DISTRIBUTORS



cencora

McKESSON

Prescribers who do not wish to use buy-and-bill should check with their preferred Specialty Pharmacy for availability. Specialty Pharmacies may obtain access to ZYNZY through the Specialty Distributors listed above

- 5 — After treatment, **complete and submit a claim** to the payer, including all necessary information. If no product was discarded, include the JZ modifier to attest to no wastage

IF YOU HAVE QUESTIONS ABOUT THIS PROCESS,
INCYTECARES AND YOUR FIELD ACCESS MANAGER MAY BE ABLE TO HELP.



Access more information online at
HCP.IncyteCARES.com/ZYNZY



Call **1-855-452-5234**
M-F, 8 AM to 8 PM ET

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

ZYNZY can cause primary or secondary adrenal insufficiency. For \geq Grade 2 adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue ZYNZY depending on severity.

ZYNZY as a Single Agent: Adrenal insufficiency occurred in 0.7% (3/440) of patients, including Grade 3 (0.5%) and Grade 2 (0.2%). ZYNZY was permanently discontinued in no patients and was withheld for 1 patient with adrenal insufficiency. All patients required systemic corticosteroids. Adrenal insufficiency resolved in 1 of the 3 patients.

ZYNZY in Combination with Carboplatin and Paclitaxel: Adrenal insufficiency occurred in 5.8% (9/154) of patients receiving ZYNZY in combination with carboplatin and paclitaxel, including Grade 3 and Grade 2 (1.9% each). Adrenal insufficiency led to permanent discontinuation of ZYNZY in 1 patient and withholding of ZYNZY in 3 patients. All patients required systemic corticosteroids. Adrenal insufficiency resolved in 4 of the 9 patients.

Please see additional Important Safety Information throughout.
Please see the Full [Prescribing Information](#).

INCYTECARES FOR ZYNYZ PATIENT SUPPORT PROGRAM OVERVIEW



When You Enroll a Patient, an IncyteCARES for ZYNYZ Representative Will:

- ▶ Call your patient to welcome them and explain their insurance coverage for ZYNYZ
- ▶ Assess your patient's eligibility for savings or financial assistance programs,* and help them enroll
- ▶ Explain the additional support and resources available to them during treatment

*Terms and conditions apply. Program terms may change at any time.
SCAC, Squamous Cell Carcinoma of the Anal Canal.



IncyteCARES Supports Your Eligible Patients With SCAC During Treatment With ZYNYZ

Our mission is to help patients start and stay on therapy by assisting with access and as-needed support.



For Eligible Patients With Commercial Health Insurance IncyteCARES for ZYNYZ Savings Program

ELIGIBLE PATIENTS CAN RECEIVE ZYNYZ FOR AS LITTLE AS \$15, SUBJECT TO CERTAIN LIMITS†

TO QUALIFY, PATIENTS MUST:

- ▶ Have commercial healthcare coverage. Patients insured under federal or state government healthcare programs—including Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program—are not eligible. Patients without healthcare coverage are also not eligible
- ▶ Be a resident of the United States or Puerto Rico
- ▶ Have a valid prescription for ZYNYZ for an FDA-approved use

†Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Program benefit applies to medication cost only and does not cover any costs to administer the medication. Valid prescription for ZYNYZ® (retifanlimab-dlwr) for an FDA-approved indication or compendia-recognized use is required. Please see the full **Patient Terms and Conditions** or call IncyteCARES for ZYNYZ at 1-855-452-5234. Update effective as of January 1, 2024.

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Hypophysitis

ZYNYZ can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts, and can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue ZYNYZ depending on severity.

Hypophysitis occurred in 0.5% (2/440, both Grade 2) of patients. No patients discontinued or withheld ZYNYZ due to hypophysitis.

All patients required systemic steroids. Hypophysitis resolved in 1 of the 2 patients.

Please see additional Important Safety Information throughout.
Please see the Full [Prescribing Information](#).

INCYTECARES FOR ZYNYZ PATIENT SUPPORT PROGRAM OVERVIEW



Enroll Your Eligible Patients in IncyteCARES for ZYNYZ



Completing the enrollment form takes about 15 minutes.

Simply download and complete the form, then fax it to 1-855-525-7207.

Visit HCP.IncyteCARES.com/ZYNYZ for more information

Other Financial Assistance and Support Options

When you enroll your patient in IncyteCARES for ZYNYZ, we will also review their eligibility for the following programs:



*For Eligible Patients Who Are
Uninsured or Underinsured for ZYNYZ*

**IncyteCARES for ZYNYZ
Patient Assistance Program**



For All Patients

**Information About
Nonprofit or Other
Support Organizations**

The IncyteCARES Team Is Available by Phone Every Weekday



Call 1-855-452-5234, M-F, 8 AM to 8 PM ET
Visit HCP.IncyteCARES.com/ZYNYZ to learn more

IMPORTANT SAFETY INFORMATION (CONT'D)

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Thyroid Disorders

ZYNYZ can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue ZYNYZ depending on severity. Thyroiditis occurred in 0.7% (3/440, all Grade 1) of patients. No patients discontinued or withheld ZYNYZ due to thyroiditis. Thyroiditis resolved in 1 of the 3 patients.

Hypothyroidism

Hypothyroidism occurred in 10% (42/440) of patients receiving ZYNYZ, including Grade 2 (4.8%). No patients discontinued due to hypothyroidism. ZYNYZ was withheld in 0.5% of patients.

Systemic corticosteroids were required for 1 patient, and 79% (33/42) of patients received endocrine therapy.

Please see additional Important Safety Information throughout.

Please see the Full [Prescribing Information](#).

Severe and Fatal Immune-Mediated Adverse Reactions (cont'd)

Hyperthyroidism

Hyperthyroidism occurred in 6% (24/440) of patients receiving ZYNZY, including Grade 2 (2.5%). ZYNZY was not discontinued in any patient and was withheld in 1 patient. Systemic corticosteroids were required for 13% (3/24) of patients, and 46% (11/24) of patients received endocrine therapy.

Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold ZYNZY depending on severity.

Type 1 diabetes mellitus occurred in 0.2% (1/440) of patients, including Grade 3 (0.2%) adverse reactions.

Immune-Mediated Nephritis with Renal Dysfunction

ZYNZY can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 1.6% (7/440) of patients receiving ZYNZY, including Grade 4 (0.5%), Grade 3 (0.7%), and Grade 2 (0.5%). Nephritis led to permanent discontinuation of ZYNZY in 0.9% of patients and withholding in 1 patient.

Systemic corticosteroids were required in 57% (4/7) of patients. Nephritis resolved in 3/7 patients.

Immune-Mediated Dermatologic Adverse Reactions

ZYNZY can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with PD-1/PD-L1-blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue ZYNZY depending on severity.

Immune-mediated skin reactions occurred in 8% (36/440) of patients, including Grade 3 (1.1%) and Grade 2 (7%). Immune-mediated dermatologic adverse reactions led to permanent discontinuation of ZYNZY in 1 patient and withholding in 2.3% of patients.

Systemic corticosteroids were required in 25% (9/36) of patients. Immune-mediated dermatologic adverse reactions resolved in 75% (27/36) of patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of < 1% in 440 patients who received ZYNZY or were reported with the use of other PD-1/PD-L1-blocking antibodies, including severe or fatal cases.

Cardiac/vascular: myocarditis, pericarditis, vasculitis

Gastrointestinal: pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis

Musculoskeletal: myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica

Neurological: meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy

Ocular: uveitis, iritis, and other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.

Endocrine: hypoparathyroidism

Other (Hematologic/Immune): hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.

Infusion-Related Reactions

A severe infusion-related reaction (Grade 3) occurred in 1 (0.2%) of 440 patients receiving ZYNZY as a single agent. Monitor patients for signs and symptoms; interrupt or slow the rate of infusion or permanently discontinue ZYNZY based on severity of reaction. Consider premedication with an antipyretic and/or an antihistamine for patients who have had previous systemic reactions to infusions of therapeutic proteins.

Complications of Allogeneic HSCT

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1-blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause), which may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT.

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1-blocking antibody prior to or after an allogeneic HSCT.

Embryo-Fetal Toxicity

ZYNYZ can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus, resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose.

Lactation

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.

Adverse Reactions

Inoperable Locally Recurrent or Metastatic SCAC: ZYNYZ in Combination with Carboplatin and Paclitaxel

The safety of ZYNYZ in patients with inoperable locally recurrent or metastatic SCAC was evaluated in 154 patients enrolled in the POD1UM-303 trial.

Serious adverse reactions occurred in 47% of patients receiving ZYNYZ in combination with carboplatin and paclitaxel. The most frequent serious adverse reactions ($\geq 2\%$ of patients) were sepsis (3.2%), pulmonary embolism (3.2%), diarrhea (2.6%), and vomiting (2.6%).

In patients receiving ZYNYZ in combination with carboplatin and paclitaxel, ZYNYZ was permanently discontinued due to an adverse reaction in 11% of patients. Adverse reactions that resulted in permanent discontinuation of ZYNYZ included immune-mediated enterocolitis (2 patients) and warm autoimmune hemolytic anemia, hepatitis, adrenal insufficiency, blood bilirubin increased, AST increased, blood alkaline phosphatase increased, arthritis, encephalopathy, peripheral sensorimotor neuropathy, hypothyroidism, immune-mediated cholangitis, pruritus, malaise, and rash (1 patient each).

Dosage interruptions due to an adverse reaction, excluding temporary interruptions due to infusion-related reactions, occurred in 55% of patients who received ZYNYZ in combination with carboplatin and paclitaxel. Adverse reactions that resulted in dosage

interruptions in $\geq 2\%$ of patients were neutropenia, anemia, thrombocytopenia, leukopenia, fatigue, COVID-19, and urinary tract infection.

The most common ($\geq 20\%$) adverse reactions were fatigue, peripheral neuropathy, nausea, alopecia, diarrhea, musculoskeletal pain, constipation, hemorrhage, rash, vomiting, decreased appetite, pruritus, and abdominal pain.

Platinum-refractory Intolerant Locally Recurrent or Metastatic SCAC: ZYNYZ as a Single Agent

The safety of ZYNYZ in patients with platinum-refractory intolerant locally recurrent or metastatic SCAC was evaluated in 94 patients in the POD1UM-202 trial.

Serious adverse reactions occurred in 40% of patients receiving ZYNYZ. The most frequent serious adverse reactions ($\geq 2\%$ of patients) were non-urinary tract infection, perineal pain, abdominal pain, anemia, hemorrhage, diarrhea, pyrexia, urinary tract infection, musculoskeletal pain, and dyspnea.

Permanent discontinuation of ZYNYZ due to an adverse reaction occurred in 4.3% of patients. These adverse reactions included diarrhea, non-urinary tract infection, perineal pain, and rash.

Dosage interruptions due to an adverse reaction occurred in 21% of patients who received ZYNYZ. Adverse reactions that resulted in dose delay in $\geq 2\%$ of patients who received ZYNYZ were non-urinary tract infection, rash, diarrhea, abdominal pain, hemorrhage, musculoskeletal pain, pyrexia, and urinary tract infection.

The most common ($\geq 10\%$) adverse reactions that occurred in patients receiving ZYNYZ were fatigue, musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite, constipation, abdominal pain, dyspnea, pyrexia, vomiting, cough, pruritus, hypothyroidism, headache, and decreased weight.

Please see the Full Prescribing Information.

ZYNYZ[®]
retifanlimab-dlwr
Injection 500 mg



ZYNYZ and the ZYNYZ logo are registered trademarks of Incyte.
Incyte and the Incyte logo are registered trademarks of Incyte.
All other trademarks are the property of their respective owners.
© 2025, Incyte. MAT-RET-00256 05/25